CD146 interaction with integrin β1 activates LATS1-YAP signaling and induces radiation-resistance in breast cancer cells

Cancer Lett. 2022 Oct 10:546:215856. doi: 10.1016/j.canlet.2022.215856. Epub 2022 Aug 6.

Abstract

Radiotherapy is an indispensable modality in comprehensive treatment of breast cancer. However, inherent or acquired radiation resistance of tumors compromises the efficacy of radiotherapy. Herein, we found that CD146, a unique epithelial-to-mesenchymal transition (EMT) inducer particularly highly expressed in triple-negative breast cancer (TNBC), is dramatically induced by ionizing irradiation. Further study demonstrates that CD146 promotes tumor cell radioresistance in vitro and in vivo. Specifically, we report the underlying mechanism that CD146 activates YAP protein, and drives its relocation from plasma to nucleus by regulating LATS1, and promoting abnormal DNA damage repair, as well as inducing EMT and stemness. Moreover, CD146 can form a novel co-receptor complex with integrin β1 and induces radiation-resistance in breast cancer. Dual inhibition of CD146 and integrin β1 activity had a stronger inhibitory effect on breast cancer tumor growth and synergistically increased their sensitivity to radiotherapy. This study identifies a unique function of CD146 implicates with integrin β1 and YAP signaling, contributing to radiation resistance. Targeted therapy against CD146 or inhibition of integrin β1 is a potential strategy to overcome radiotherapeutic resistance of breast cancer.

Keywords: Breast cancer; Cluster of differentiation 146; Hippo/YAP pathway; Integrin β1; Radioresistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD146 Antigen
  • Cell Line, Tumor
  • Humans
  • Integrin beta1*
  • Protein Serine-Threonine Kinases
  • Triple Negative Breast Neoplasms*

Substances

  • CD146 Antigen
  • Integrin beta1
  • LATS1 protein, human
  • Protein Serine-Threonine Kinases